HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on InflaRx (NASDAQ:IFRX) and maintained a price target of $8, as per analyst Edward White.
September 25, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on InflaRx, maintaining a price target of $8. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100